Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
To demonstrate the efficacy of enobosarmin the treatment of androgen receptor positive (AR+)
and estrogen receptor positive (ER+) metastatic breast cancer (MBC) as measured by
radiographic progression free survival (rPFS).